# Vir Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vir-biotechnology

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.vir.bio
- Latest round: Seed (Jan 6, 2017)
- Investors on record: 4

## About

Based in the US, Vir Biotechnology, Inc. (VIR) is a biotechnology firm focused on developing innovative therapies aimed at addressing infectious diseases and oncology through advanced antibody technologies.Vir Biotechnology, Inc. was founded in 2016 and operates out of San Francisco, US. The company specializes in the development of therapies targeting infectious diseases and cancer using its own proprietary technologies. The founder, Robert Nelsen, has a background in biotechnology and has previously been involved in founding other companies. In October 2023, Vir Biotechnology, Inc. received approximately USD 50 million in grant funding from Biomedical Advanced Research and Development Authority. Marianne De Backer is the CEO.Vir Biotechnology is dedicated to creating advanced therapies utilizing its next-generation antibody platform and the proprietary PRO-XTEN™ protease-releasable masking technology. The company’s initiatives focus on chronic hepatitis delta, COVID-19, and Ebola, with products designed to enhance immune responses. Its offerings are primarily targeted towards healthcare providers and institutions in North America and Europe, designed to meet the needs of patients affected by these health challenges.Vir Biotechnology plans to launch upcoming products developed from its advanced antibody platform and PRO-XTEN™ technology, although specific release dates have not been disclosed. The company is also targeting expansion into new international markets, with strategic efforts focused on Europe and Asia. The funding obtained from the most recent deal in July 2020 will support the advancement of these initiatives, enabling the company to enhance its R&D capabilities and accelerate the development of its therapeutic candidates.

## Funding rounds

- Seed, Jan 6, 2017 — Alta Partners, ARCH Venture Partners, Altitude Life Science Ventures, Bill & Melinda Gates Foundation

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Seed
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Seed
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Seed
- Bill & Melinda Gates Foundation — Seed